Significant fracture risk reductions following 18 months of treatment1

TYMLOS significantly reduced the risk of vertebral fractures1

Percentage of postmenopausal women with osteoporosis with new vertebral fractures at 18 months1

Proportion of postmenopausal women with vertebral fractures after 18 months treatment with TYMLOS vs placebo

P<0.0001.1
Results reported in the modified intent-to-treat (ITT) population, which included patients who had both pretreatment and posttreatment spine radiographs.1
Primary endpoint.1

TYMLOS provided a 3.6% ARR in new vertebral fractures at 18 months1

7x more women on placebo experienced new vertebral fractures at 18 months versus those on TYMLOS1

TYMLOS significantly reduced the risk of nonvertebral fractures1

Cumulative incidence of nonvertebral fractures* at 19 months (18 months of treatment plus 1 month of follow-up without treatment)1

Nonvertebral fracture risk after 18 months TYMLOS treatment

Nonvertebral fractures excluded those of the sternum, patella, toes, fingers, skull, and face, and those associated with high trauma.1

P=0.049.1

P-value based on the log-rank test.1

Results reported in ITT population, which included patients randomized in the efficacy study.1

Secondary endpoint.2

TYMLOS provided a 2.0% ARR in nonvertebral fractures at 19 months1

Risk reductions across demographics1

TYMLOS demonstrated consistent reductions in the risk of vertebral and nonvertebral fractures regardless of1:

Age

BMD at baseline

Years since menopause

Presence or absence
of prior vertebral or
nonvertebral fracture

View BMD results from the
TYMLOS efficacy study

References: 1. TYMLOS™ [prescribing information]. Waltham, MA: Radius Health, Inc; 2017. 2. A randomized, double-blind, placebo-controlled, comparative phase 3 multicenter study to evaluate the safety and efficacy of BA058 for injection for prevention of fracture in ambulatory postmenopausal women with severe osteoporosis and at risk of fracture [supplement 2]. Waltham, MA: Radius Health, Inc; 2015. http://jamanetwork.com/data/Journals/JAMA/935644/JOI160092supp2_prod.pdf. Accessed June 14, 2017.

Back to Top

See Change in BMD

TYMLOS provided significant increases in BMD1

Percentage of change in bone mineral density in postmenopausal women after 18 months of treatment with TYMLOS vs placebo

Mean percent change from baseline in BMD in postmenopausal women with osteoporosis at 18 months1

Percentage of change in bone mineral density in postmenopausal women after 18 months of treatment with TYMLOS vs placebo

Mean percent change from baseline in BMD in postmenopausal women with osteoporosis at 18 months1

Percentage of change in bone mineral density in postmenopausal women after 18 months of treatment with TYMLOS vs placebo

Mean percent change from baseline in BMD in postmenopausal women with osteoporosis at 18 months1

Percentage of change in bone mineral density in postmenopausal women after 18 months of treatment with TYMLOS vs placebo

P<0.0001.1

Results reported in ITT population, which included patients randomized in the efficacy study; mean percentage change in BMD was last observation carried forward (LOCF).1

Secondary endpoint2; BMD captured with dual-energy absorptiometry (DXA) scans.3

BMD across demographics1

TYMLOS demonstrated consistent BMD increases for a wide range of postmenopausal women, regardless of1:

Age

Race/Ethnicity

Years since
menopause


BMD at baseline

Presence or absence of prior
vertebral or nonvertebral fracture

Geographic region

See the bone histology of TYMLOS

References: 1. TYMLOS™ [prescribing information]. Waltham, MA: Radius Health, Inc; 2017. 2. Miller PD, Hattersley G, Riis BJ, et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA. 2016;316(7):722-733. [Erratum: JAMA. 2017;317(4):442.] 3. A randomized, double-blind, placebo-controlled, comparative phase 3 multicenter study to evaluate the safety and efficacy of BA058 for injection for prevention of fracture in ambulatory postmenopausal women with severe osteoporosis and at risk of fracture [supplement 2]. Waltham, MA: Radius Health, Inc; 2015. http://jamanetwork.com/data/Journals/JAMA/935644/JOI160092supp2_prod.pdf. Accessed June 14, 2017.

Back to Top

See Extension Study

Efficacy results achieved with TYMLOS were continued after transitioning to alendronate1

The extension study was designed to assess whether clinical benefits achieved at
18 months with TYMLOS, an anabolic, would continue at 25 months with alendronate1,2*

New vertebral fractures: Risk reduction achieved with TYMLOS continued after transitioning to alendronate1

Percentage of postmenopausal women with osteoporosis with new vertebral fractures at 25 months1*

Percentage of postmenopausal women with subsequent vertebral fractures at 25 months of treatment with TYMLOS vs placebo

TYMLOS/alendronate provided a 3.9% ARR in new vertebral fractures at 25 months1

Data included 18 months of TYMLOS or placebo, followed by 1 month of no treatment, then 6 months on alendronate.1

P<0.0001.1

Results reported in the modified ITT, which included patients who had both pretreatment and posttreatment spine radiographs.1

Primary endpoint.1,3

TYMLOS/alendronate provided a 3.9% ARR in
new vertebral fractures at 25 months1

Almost 8 times more women in the placebo/alendronate group experienced new vertebral fractures versus
those in the TYMLOS/alendronate group at 25 months1

Nonvertebral fractures: Risk reduction achieved with TYMLOS continued after transitioning to alendronate1

Cumulative incidence of nonvertebral
fractures* over 25 months1†

Incidence of nonvertebral fractures in patients treated with TYMLOS vs placebo in first 25 months

TYMLOS/alendronate provided a 2.9% ARR in nonvertebral fractures at 25 months1

Results reported in ITT population, which included patients randomized in the efficacy study.1

Nonvertebral fractures excluded those of the sternum, patella, toes, fingers, skull, and face, and those associated with high trauma.1

Data included 18 months of TYMLOS or placebo, followed by 1 month of no treatment, then 6 months on alendronate.1

P=0.017.1

P-value based on the log-rank test.1

P-value based on the log-rank test.1

P=0.017.1

Secondary endpoint.3

TYMLOS/alendronate provided a 2.9% ARR in nonvertebral fractures at 25 months1

BMD increases achieved with TYMLOS continued after transitioning to alendronate1

Patients who transitioned from TYMLOS to alendronate achieved at least a 3-fold increase in BMD versus placebo to alendronate at these sites at 25 months1

Comparison of change in bone mineral density in patients treated with TYMLOS vs placebo

Mean percent change from baseline in BMD in postmenopausal women with osteoporosis at 25 months1*

Comparison of change in bone mineral density in patients treated with TYMLOS vs placebo

Mean percent change from baseline in BMD in postmenopausal women with osteoporosis at 25 months1*

Comparison of change in bone mineral density in patients treated with TYMLOS vs placebo

Mean percent change from baseline in BMD in postmenopausal women with osteoporosis at 25 months1*

Comparison of change in bone mineral density in patients treated with TYMLOS vs placebo

Data included 18 months of TYMLOS or placebo, followed by 1 month of no treatment, then 6 months on alendronate.1

P<0.0001.1

Results reported in ITT population, which included patients enrolled in the extension study; mean percent change in BMD was LOCF.1

Secondary endpoint; BMD captured with DXA scans.3

Learn more about Together with Tymlos
offerings and the savings card

References: 1. TYMLOS™ [prescribing information]. Waltham, MA: Radius Health, Inc; 2017. 2. Moreira CA, Fitzpatrick LA, Wang Y, Recker RR. Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: the ACTIVE phase 3 trial. Bone. 2017;97:314-319. 3. Cosman F, Miller PD, Williams GC, et al. Eighteen months of treatment with subcutaneous abaloparatide followed by 6 months of treatment with alendronate in postmenopausal women with osteoporosis: results of the ACTIVExtend trial. Mayo Clin Proc. 2017;92(2):200-210.

Back to Top

This site is intended for HCPs in the United States.

All other trademarks are the property of their respective owners.

© 2017 Radius Health, Inc.   All rights reserved.    10/17.   TYM-US-00647

This site is intended for HCPs in the United States.
TYMLOS is a trademark of Radius Health, Inc.
All other trademarks are the property of their respective owners.

© 2017 Radius Health, Inc.
All rights reserved. 10/17.
TYM-US-00647